SOX plus sintilimab vs P-SOX vs SOX as neoadjuvant therapy in advanced gastric cancer: Efficacy and safety

doi:10.4251/wjgo.v17.i8.109646

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (226)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series, Tables (1-4) series.

Item

Count

PDF

HTML

162

Figures (1-6)

Tables (1-4)

Sum=213

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=4

Aug 15, 2025 (publication date) through Aug 17, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Aug 15, 2025; 17(8): 109646
Published online Aug 15, 2025. doi: 10.4251/wjgo.v17.i8.109646

Table 1 Basic patient characteristics and short-term efficacy, n (%)

Variables	Total (n = 299)	P-SOX (n = 118)	SOX (n = 100)	SOX + XDL (n = 81)	P value
Age					0.451
≤ 60	164 (54.8)	69 (58.5)	50 (50)	45 (55.6)
> 60	135 (45.2)	49 (41.5)	50 (50)	36 (44.4)
Gender					0.056
Male	240 (80.3)	102 (86.4)	79 (79)	59 (72.8)
Female	59 (19.7)	16 (13.6)	21 (21)	22 (27.2)
ASA					0.666
1 + 2	261 (87.3)	102 (86.4)	86 (86)	73 (90.1)
3	38 (12.7)	16 (13.6)	14 (14)	8 (9.9)
Differentiation					0.238
Well	82 (27.4)	33 (28)	28 (28)	21 (25.9)
Moderate	80 (26.8)	25 (21.2)	34 (34)	21 (25.9)
Poorly	137 (45.8)	60 (50.8)	38 (38)	39 (48.1)
cT stage					0.264
2	71 (23.7)	26 (22)	26 (26)	19 (23.5)
3	155 (51.8)	56 (47.5)	51 (51)	48 (59.3)
4	73 (24.4)	36 (30.5)	23 (23)	14 (17.3)
cN stage					0.066
Negative	92 (30.8)	41 (34.7)	22 (22)	29 (35.8)
Positive	207 (69.2)	77 (65.3)	78 (78)	52 (64.2)
cTNM					0.083
II	148 (49.5)	56 (47.5)	47 (47)	45 (55.6)
IIIA	28 (9.4)	13 (11)	11 (11)	4 (4.9)
IIIB	62 (20.7)	22 (18.6)	17 (17)	23 (28.4)
IIIC	61 (20.4)	27 (22.9)	25 (25)	9 (11.1)
RECIST 1.1					0.099
Ineffective	117 (39.1)	48 (40.7)	45 (45)	24 (29.6)
Effective	182 (60.9)	70 (59.3)	55 (55)	57 (70.4)
Lauren					0.616
Diffuse	107 (35.8)	42 (35.6)	39 (39)	26 (32.1)
Mixed	141 (47.2)	58 (49.2)	41 (41)	42 (51.9)
Intestinal	51 (17.1)	18 (15.3)	20 (20)	13 (16)
Tumor location					0.955
Upper	75 (25.1)	29 (24.6)	26 (26)	20 (24.7)
Middle	116 (38.8)	44 (37.3)	41 (41)	31 (38.3)
Lower	108 (36.1)	45 (38.1)	33 (33)	30 (37)
TRG					0.320
Effective	262 (87.6)	104 (88.1)	84 (84)	74 (91.4)
Ineffective	37 (12.4)	14 (11.9)	16 (16)	7 (8.6)
Tumor diameter					0.152
≤ 2	156 (52.2)	55 (46.6)	57 (57)	44 (54.3)
2-5	79 (26.4)	29 (24.6)	26 (26)	24 (29.6)
≥ 5	64 (21.4)	34 (28.8)	17 (17)	13 (16)

Tumor location is classified as upper 1/3, middle 1/3, lower 1/3, diffuse TNM staging according to the American Cancer Consortium. ASA: American Society of Anesthesiologists Score; RECIST: Response Evaluation Criteria in Solid Tumors; TRG: Tumor regression grade; XDL: Sintilimab.

Citation: Wang YC, Zhang CG, Wang YW, Guo C, Pan T, Yu PJ, Cai BJ, Ding RH, Qiang JL, Deng CQ, Hu CH, Xu YH. SOX plus sintilimab vs P-SOX vs SOX as neoadjuvant therapy in advanced gastric cancer: Efficacy and safety. World J Gastrointest Oncol 2025; 17(8): 109646
URL: https://www.wjgnet.com/1948-5204/full/v17/i8/109646.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i8.109646